Crizotinib-Resistant ROS1 G2101A Mutation Associated With Sensitivity to Lorlatinib in ROS1-Rearranged NSCLC: Case Report

Abstract

ROS1: gene rearrangements occur in 1% to 2% of NSCLC. Acquired “on-target” mutations within the ROS1 kinase domain are a known resistance mechanism to the first-line ROS1 inhibitor crizotinib. Here, we report the first case of a patient with an acquired ROS1 G2101A resistance mutation after first-line crizotinib, who responded to lorlatinib. The response was dramatic but short in duration.

Keywords

• Non–small cell lung cancer
• ROS1 fusion
• ctDNA
• Lorlatinib
• Case report